<DOC>
	<DOC>NCT02322957</DOC>
	<brief_summary>This study is designed to evaluate the potential for a PK drug-drug interaction between FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.</brief_summary>
	<brief_title>A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Capable of giving written informed consent Nontobacco user for at least 3 months prior to selection Healthy on the basis of physical examination, medical history, ECG and clinical laboratory testing at screening (must NOT meet the following) Infected with Hepatitis A, B, C, or HIV History of or any current medical condition which could impact safety of the participant A positive urine drug test Consumption of more than 2 units of alcoholic beverages per day or more than 14 per week Received an investigational drug or vaccine or used an investigational medical device within 3 months or 5 halflives before the planned start of treatment or prior treatment with FV100 Subjects who have used any drugs or substances known to inhibit or induce cytochrome(CYP) P450 enzymes and/or Pgp within 28 days prior to the first dose and throughout study Subjects who have, within 2 weeks prior to the first dose of study drug, ingested grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family or charbroiled meats</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>